Therapeutic targeting RORγ with natural product N-hydroxyapiosporamide for small cell lung cancer by reprogramming neuroendocrine fate.
Chen J, Hu Y, Zhang J, Wang Q, Wu X, Huang W, Wang Q, Cai G, Wang H, Ou T, Feng W, Liu P, Liu Y, Wang J, Huang J, Wang J.
Chen J, et al. Among authors: wang h, wang j, wang q.
Pharmacol Res. 2022 Apr;178:106160. doi: 10.1016/j.phrs.2022.106160. Epub 2022 Mar 6.
Pharmacol Res. 2022.
PMID: 35259480